Sanofi ( Sanofi)

Primary tabs

Sanofi's picture

Management

Contact Address

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patient's needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

Sanofi press release, blog etc

Tue, 04/15/2025 - 11:16 Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
Fri, 03/14/2025 - 15:15 Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
Thu, 02/01/2024 - 23:26 Sanofi launches Beyfortus (nirsevimab-alip) Reservation Program for 2024-2025 RSV season in U.S.
Thu, 10/06/2022 - 15:30 enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Wed, 08/03/2022 - 13:08 Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare
Tue, 07/26/2022 - 03:21 Sanofi partners with Howard University in an unprecedented pharmacy fellowship program
Sun, 07/10/2022 - 01:05 Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
Wed, 06/22/2022 - 03:27 Sanofi Statement on ACIP 2022-2023 Influenza Recommendations for People 65+
Wed, 06/01/2022 - 06:38 FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
Thu, 04/14/2022 - 15:06 Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
Wed, 03/09/2022 - 11:35 Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
Thu, 03/03/2022 - 00:01 Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Tue, 11/30/2021 - 19:48 Sanofi offers all employees worldwide 14 weeks paid parental leave to ensure workplace equality
Thu, 10/07/2021 - 03:44 Positive results from the first study of high-dose quadrivalent influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
Thu, 09/09/2021 - 10:32 Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Thu, 06/17/2021 - 16:57 Newly licensed US manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent (influenza vaccine)
Fri, 06/11/2021 - 17:25 Sanofi provides update on Aubagio (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.
Wed, 05/19/2021 - 16:42 Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
more

InfoBox

HomePagewww.sanofi.us
Facebookwww.facebook.com/sanofiUS
Twitterwww.twitter.com/SanofiUS
Pinterestwww.pinterest.com/sanofius
LinkedInwww.linkedin.com/company/sanofi-
Wikipediaen.wikipedia.org/wiki/Sanofi